for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Baxter International Inc

BAX.N

Latest Trade

81.45USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

69.12

 - 

95.17

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
81.45
Open
--
Volume
--
3M AVG Volume
65.30
Today's High
--
Today's Low
--
52 Week High
95.17
52 Week Low
69.12
Shares Out (MIL)
506.23
Market Cap (MIL)
41,379.38
Forward P/E
--
Dividend (Yield %)
1.20

Next Event

Q3 2020 Baxter International Inc Earnings Release

Latest Developments

More

Baxter Announces U.S. FDA De Novo Authorization For Theranova Dialyzers Enabling HDx Therapy

Baxter Obtains U.S. FDA Emergency Use Authorization For Regiocit Replacement Solution Used In CRRT

Baxter Reports Q2 Gaap Earnings Per Share $0.48

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Baxter International Inc

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Industry

Medical Equipment & Supplies

Contact Info

1 Baxter Pkwy

DEERFIELD, IL

60015-4625

United States

+1.847.9482000

https://www.baxter.com/

Executive Leadership

Jose E. Almeida

Chairman of the Board, President, Chief Executive Officer

James K. Saccaro

Chief Financial Officer, Executive Vice President

Brian Stevens

Senior Vice President, Chief Accounting Officer, Controller

Sean B. W. Martin

Senior Vice President, General Counsel

Jeanne K. Mason

Senior Vice President - Human Resources

Key Stats

1.89 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

10.6K

2018

11.1K

2019

11.4K

2020(E)

11.4K
EPS (USD)

2017

2.480

2018

3.050

2019

3.310

2020(E)

3.062
Price To Earnings (TTM)
58.35
Price To Sales (TTM)
3.63
Price To Book (MRQ)
5.13
Price To Cash Flow (TTM)
26.89
Total Debt To Equity (MRQ)
78.42
LT Debt To Equity (MRQ)
74.50
Return on Investment (TTM)
4.71
Return on Equity (TTM)
4.01

Latest News

Latest News

BRIEF-Baxter Announces FDA Clearance Of Altapore Shape Bioactive Bone Graft For Use In Surgery

* BAXTER ANNOUNCES U.S. FDA CLEARANCE OF ALTAPORE SHAPE BIOACTIVE BONE GRAFT FOR USE IN SURGERY Source text for Eikon: Further company coverage:

BRIEF-Baxter Highlights New Data On Improving Care For Dialysis Patients

* BAXTER HIGHLIGHTS NEW DATA ON THE ROLE TECHNOLOGIES PLAY IN IMPROVING CARE FOR DIALYSIS PATIENTS DURING THE 57TH ERA-EDTA VIRTUAL CONGRESS

Mexico orders probe into alleged graft linked to ex-president

Mexican President Andres Manuel Lopez Obrador on Wednesday ordered an investigation into allegations the former government irregularly awarded lucrative contracts to a firm allegedly tied to the family of his predecessor, Enrique Pena Nieto.

BRIEF-Baxter Receives CE Marking For EVO IQ Syringe Infusion System

* BAXTER RECEIVES CE MARKING AND AUSTRALIAN REGULATORY APPROVAL FOR EVO IQ SYRINGE INFUSION SYSTEM, BUILDING ON SMART PUMP PLATFORM Source text for Eikon: Further company coverage:

BRIEF-Baxter Announces Results Of Clinical Trial On Benefits Of Dynamic Fluid Management In Septic Shock Patients

* BAXTER ANNOUNCES RESULTS OF CLINICAL TRIAL ON BENEFITS OF DYNAMIC FLUID MANAGEMENT IN SEPTIC SHOCK PATIENTS

BRIEF-Baxter Reports First-Quarter 2020 Results

* Q1 REVENUE $2.8 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.75 BILLION

BRIEF-Baxter Says Audit Committee To Continue To Actively Oversee Remedial Actions

* BAXTER - IN 2020, AUDIT COMMITTEE TO CONTINUE TO ACTIVELY OVERSEE REMEDIAL ACTIONS TO HELP ENSURE THAT EVENTS LEADING TO RESTATEMENT DO NOT RECUR

Baxter to hire 2,000 employees as demand for medical products surge

Baxter International Inc <BAX.N> said on Wednesday it would hire up to 2,000 employees globally, including 800 people in the United States, in response to higher demand for its medical devices due to rise in cases of the new coronavirus infections.

BRIEF-Baxter Provides Update On Covid-19 Response Efforts

* BAXTER INTERNATIONAL INC - HIRING UP TO 2,000 NEW EMPLOYEES GLOBALLY

Pfizer, Baxter defeat intravenous saline solutions antitrust case

A federal judge has dismissed a proposed class action accusing Baxter International and Pfizer Inc's Hospira of engaging in an anticompetitive scheme to restrict the output of intravenous saline solutions in order to boost prices.

BRIEF-Baxter To Host Its Annual Meeting Of Stockholders In Virtual Format

* BAXTER TO HOST ITS ANNUAL MEETING OF STOCKHOLDERS IN VIRTUAL FORMAT Source text for Eikon: Further company coverage:

BRIEF-Ameren Corp Says CEO Warner Baxter's FY 2019 Total Compensation Was $9.7 Million

* AMEREN CORP SAYS CEO WARNER BAXTER'S FY 2019 TOTAL COMPENSATION WAS $9.7 MILLION VERSUS $8.5 MILLION IN FY 2018 - SEC FILING

BRIEF-Baxter International's James Saccaro Tested Positive For Covid-19 Virus

* BAXTER INTERNATIONAL INC - JAMES K. SACCARO, CFO, TESTED POSITIVE FOR COVID-19 VIRUS

BRIEF-Baxter International Inc Says CEO José E. Almeida's 2019 Total Compensation Was $13.9 Million

* BAXTER INTERNATIONAL INC SAYS CEO JOSÉ E. ALMEIDA'S 2019 TOTAL COMPENSATION WAS $13.9 MILLION VERSUS $15.6 MILLION IN 2018 – SEC FILING

BRIEF-Baxter Reports Q4 Loss Per Share $0.05 From Continuing Operations

* BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS, COMPLETES FINANCIAL RESTATEMENT PROCESS

BRIEF-Baxter International Files For Non-Timely 10-K With U.S. SEC

* BAXTER INTERNATIONAL INC - FILES FOR NON-TIMELY 10-K WITH U.S. SEC

BRIEF-Baxter International Says Got 510(K) Clearance From U.S. FDA For New Generation Of Its Peri-Strips Dry With Veritas Collagen Matrix Product

* SAYS GOT 510(K) CLEARANCE FROM U.S. FDA FOR NEW GENERATION OF ITS PERI-STRIPS DRY WITH VERITAS COLLAGEN MATRIX PRODUCT Source text for Eikon: Further company coverage:

BRIEF-Baxter International Says Financial Statements As Of Dec 31, 2018 & 2017, For Yrs Ended Dec 31, 2018, 2017 & 2016, Should No Longer Be Relied Upon

* BAXTER INTERNATIONAL - FINANCIAL STATEMENTS AS OF DEC 31, 2018 & 2017, FOR YRS ENDED DEC 31, 2018, 2017 & 2016, SHOULD NO LONGER BE RELIED UPON

BRIEF-Baxter And Cosmed Announce U.S. FDA 510(K) Clearance Of Q-Nrg+ Indirect Calorimetry Device

* BAXTER AND COSMED ANNOUNCE U.S. FDA 510(K) CLEARANCE OF Q-NRG+ INDIRECT CALORIMETRY DEVICE

Sanofi agrees to sell Seprafilm to Baxter for $350 million

Medical supply company Baxter International Inc <BAX.N> said on Monday it had agreed to buy Sanofi <SASY.PA>'s Seprafilm unit, which makes specialist surgical products, for $350 million in cash.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up